Japan’s Kyorin Pharmaceutical has entered into a global license agreement with Swiss pharma giant Novartis relating to ...

Novartis is further bolstering its preclinical pipeline and continuing its hunt for a Xolair successor, nailing down a ...

M223, a preclinical drug for inflammatory diseases, with potential milestone payments of $777.5M plus royalties.

Ice cream for breakfast? Why not? Here's what makes ice cream a good breakfast addition, and ways to pair those frozen scoops ...

On Wednesday, Teladoc Health reported that its 2024 revenue dropped 1% to $2.57 billion. The company projected a revenue ...

Kyorin Pharma has signed a deal with digital health firm Hyfe to develop a digital therapeutic (DTx) for people with chronic ...

Kyorin Pharmaceutical Co. Ltd. struck two licensing deals recently, including one with Hyfe Inc. Feb. 25 to develop the world ...

In Regeneron Pharmaceuticals Inc.’s phase I/II Chord study of 12 children with genetic hearing loss tied to the variants of the otoferlin gene, 10 out of 11 have showed notable improvements in their ...

Under this agreement, KYORIN obtains an option for the license of the right to develop and commercialize CYR-064 in Japan and will pay an option fee to Cyrano. Upon exercising the option and ...

DELRAY BEACH, Fla., Feb. 18, 2025 /PRNewswire/ -- Cyrano Therapeutics, Inc., a clinical-stage regenerative medicine company pioneering the development of treatments for smell loss, announced ...